Take Homes in Multiple Myeloma

Take Homes in Multiple Myeloma

Source:

Rafae A, et al. Abstract e20034. Presented at: ASCO Annual Meeting; June 4-8, 2021 (virtual meeting).

Disclosures: Gasparetto reports leadership fees from Celgene; consulting/advising for AbbVie/Genentech, Celgene, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Sanofi; speakers’ fees from GlaxoSmithKlinem Karyopharm Therapeutics, Sanofi; and travel expenses from Celgene and Karyopharm Therapeutics
June 24, 2021
1 min watch
Save

VIDEO: Expert discusses potential of bispecific T-cell engagers in multiple myeloma

Source:

Rafae A, et al. Abstract e20034. Presented at: ASCO Annual Meeting; June 4-8, 2021 (virtual meeting).

Disclosures: Gasparetto reports leadership fees from Celgene; consulting/advising for AbbVie/Genentech, Celgene, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Sanofi; speakers’ fees from GlaxoSmithKlinem Karyopharm Therapeutics, Sanofi; and travel expenses from Celgene and Karyopharm Therapeutics
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Cristina Gasparetto, MD, director of the multiple myeloma program at Duke University, discussed data on bispecific T-cell engagers currently being studied in relapsed and refractory multiple myeloma presented at the virtual ASCO Annual Meeting

In a video interview, Gasparetto said that the data on bispecific T-cell engagers (BiTEs) has shown promising overall responses as well as mild to moderate toxicities in most patients.

“It looks like the administration of these BiTEs is going to be favorable for the quality of life for patients,” she said. “They are given once a week subacute, so that is becoming very popular with immunotherapies.”

Gasparetto also said she’s interested in learning about whether BiTEs can be sequentially used with prior BCMA-targeted therapies.